山东新华制药股份(00719)收到瑞舒伐他汀钙片(20mg;10mg)《药品补充申请批准通知书》

智通财经
21 Jan

智通财经APP讯,山东新华制药股份(00719)公布,近日,公司收到国家药品监督管理局核准签发的瑞舒伐他汀钙片(20mg;10mg)《药品补充申请批准通知书》,批准本品上市许可持有人转让补充申请。

瑞舒伐他汀钙片(20mg;10mg)于2025年1月通过国家药品监督管理局审批,新华制药成为本品的上市许可持有人。该产品的上市,有利于丰富公司血脂调节剂他汀类药物产品线,提升公司综合竞争优势。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10